PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Targeted Therapies to Lead New Wave of Breast Cancer Treatments - Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market
Targeted Therapies to Lead New Wave of Breast Cancer Treatments

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/06/30 - Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

To thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Breast Cancer Therapeutics Markets, finds that the targeted therapies segment of the market earned revenues of $1.34 billion in 2007 and estimates this to reach $3.34 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. Breast Cancer Therapeutics Markets, send an email to Johanna Haynes, Corporate Communications, at jhaynes_pr[.]frost.com, with the following information: your full name, company name, title, telephone number, company email address, company website, city, state and country. We will send you the information via email upon receipt of the above information. All media inquiries please reply directly to johanna.haynes[.]frost.com.

The fastest growing segment of the U.S. population belongs to the aging segment, where the highest rates of breast cancer occur. The breast cancer market will remain a visibly important area of oncology. Companies are putting their research dollars into developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well.

These innovative, targeted therapies have shown the greatest promise in the market and many are touting them as the future of breast cancer treatment. Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies are rapidly becoming the standard of oncology care.

"Future research into treatment strategies will focus on drugs with clear therapeutic potential, as well as minimal side-effect profiles," says Frost & Sullivan Research Analyst Misty Hughes. "Specialized therapies such as monoclonal antibodies, angiogenesis inhibitors, and vaccines could make a significant impact through targeted mechanisms of action and minimized toxicities."

As the cost to develop new drugs increases, so does the degree of difficulty for smaller companies to develop products that make it through the approval process. These smaller companies must often seek and obtain licensing partnerships with larger corporations in order to defray costs associated with bringing new drugs to the market.

While smaller companies receive the required funds and personnel resources for developing new compounds, large enterprises expand their portfolio of potential new products, helping them proactively manage their pipelines.

"In order to attract larger companies, smaller companies must conduct well-designed pre-clinical tests that culminate in favorable results from phase I trials," notes Hughes. "The higher the potential of the investigative compound for treating more than one cancer is, the greater the likelihood of partnerships."

U.S. Breast Cancer Therapeutics Markets is part of the Pharmaceutical & Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: European market for breast cancer therapeutics, world breast cancer therapeutics market, U.S. multiple myeloma market, and the U.S. colorectal cancer market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

U.S. Breast Cancer Therapeutics Markets - N16A

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Targeted Therapies to Lead New Wave of Breast Cancer Treatments

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)